Eleusis SPAC

eleusis ELE-Psilo Target Profile Proposed Indication Proposed Proprietary Psilocin Salt Form in Formulation Ready-to-Use Vial Proposed Administration Rapid Acting Treatment of MDD Investigational Dose Range IV Infusion Potential Duration 10-to-30 min infusion of Administration ≤2 hours in-clinic 1-5mg Abuse Potential Potential reclassification if FDA Approved¹ Source: 1) Johnson, M. W. et al. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 142, 143-166. ‒‒‒‒ RIN 14

View entire presentation